id: NEW:psychedelic_assisted_therapy_access_to_alcohol_use_disorder
name: Psychedelic-Assisted Therapy Access â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:psychedelic_assisted_therapy_access
  node_name: Psychedelic-Assisted Therapy Access
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Access to psychedelic-assisted therapy (LSD or psilocybin) in clinical settings provides structured
  therapeutic intervention'
- 'Step 2: Psychedelics may induce neuroplasticity and alter default mode network activity, facilitating
  psychological insight'
- 'Step 3: Therapeutic sessions help patients process underlying trauma and psychological factors contributing
  to alcohol dependence'
- 'Step 4: Patients achieve abstinence or substantial reduction in alcohol consumption through enhanced
  treatment response'
evidence:
  quality_rating: B
  n_studies: 4
  primary_citation: 'Dakota J. Sicignano et al. 2023. "The impact of psychedelics on patients with alcohol
    use disorder: a systematic review with meta-analysis." https://doi.org/10.1080/03007995.2023.2296968'
  supporting_citations:
  - LSD studies published between 1966-1970 (historical trials cited in meta-analysis)
  - Psilocybin trial from 2022 (higher methodological quality contemporary study)
  - Additional citations require full-text access for specific author/journal details
  doi: 10.1080/03007995.2023.2296968
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Meta-analysis of randomized controlled trials found that any psychedelic therapy (LSD or
  psilocybin) enhanced odds of achieving abstinence or substantial reduction in alcohol consumption by
  2.16 times compared to placebo in double-blind trials. When inclusion criteria were relaxed, the odds
  ratio was 1.89 across 6 trials.
quantitative_effects:
  effect_size:
    value: 2.16
    type: odds_ratio
    ci_lower: 1.26
    ci_upper: 3.69
moderators:
- name: study_design_rigor
  direction: strengthens
  strength: moderate
  description: Double-blind, placebo-controlled trials showed stronger effects (OR 2.16) compared to trials
    without such controls
- name: time_period
  direction: weakens
  strength: moderate
  description: Historical studies (1966-1970) may have weaker applicability to contemporary practice compared
    to the 2022 psilocybin trial
structural_competency:
  equity_implications: This mechanism highlights how regulatory restrictions on psychedelic research and
    treatment access create structural barriers to potentially effective AUD treatments. The historical
    gap in research (1970s to 2022) reflects policy decisions that limited investigation of these therapies.
    Expanding access to evidence-based psychedelic-assisted therapy requires policy reform at federal
    and state levels. Equity implications include differential access based on clinical trial availability,
    healthcare system engagement, and potential future insurance coverage disparities.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.294319'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
